secwatch.observer — SEC 8-K summary
======================================

Issuer:     TherapeuticsMD, Inc. (TXMD)
CIK:        0000025743
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001564590-22-037633
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TherapeuticsMD Q3 revenue $20.9M, net loss $29.0M; cash drops to $27.1M
-----------------------------------------------------------------------

- Net revenue $20.9M, down 18% YoY; net loss $29.0M ($3.13/sh) vs $47.4M loss YoY.
- Operating expenses cut $22.2M YoY to $37.9M; product gross margin 82% vs 78%.
- ANNOVERA revenue $10.4M (-$1.4M YoY), Rx up 10% YoY; IMVEXXY $6.9M; BIJUVA $2.7M.
- Cash $27.1M at Sep 30, down from $65.1M at Dec 31; post-quarter $7M investment from Rubric Capital.
- Net debt and preferred stock liability $117.1M; no earnings call due to strategic alternatives review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/25743/000156459022037633/0001564590-22-037633-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/25743/000156459022037633/txmd-8k_20221114.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-037633

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer